Abstract
QT interval represents the period between the initiation of depolarization and the end of repolarization of the ventricular myocardium. Excessive prolongation of this interval may drive to a potentially fatal ventricular tachyarrhythmia known as “torsades de pointes”. Agents used to manage many endocrine disorders have been linked with QTc alterations. Among them, oral antidiabetic agents, lipid lowering and anti-obesity drugs, somatostatin analogues, thyroid and anti-thyroid agents, and adrenal steroids should be considered. Nevertheless, it is very well known that some endocrine diseases are associated with constraints in the repolarization reserve, and, as a consequence, with QTc prolongation. Besides, some disturbances in the clearance of certain drugs are more frequent in patients affected by selected endocrine entities. Taking these into account, the purpose of this article is to review the behavior of the most widely used drugs in endocrinology with regards to their potential QTc prolongation effect in human beings.
Keywords: QT interval prolongation, endocrine therapies, oral antidiabetics, thyroid drugs, HERG channel, torsades de points
Current Drug Safety
Title: Endocrine Therapies and QTc Prolongation
Volume: 5 Issue: 1
Author(s): Claudio Daniel Gonzalez, Martha de Sereday, Isaac Sinay and Silvina Santoro
Affiliation:
Keywords: QT interval prolongation, endocrine therapies, oral antidiabetics, thyroid drugs, HERG channel, torsades de points
Abstract: QT interval represents the period between the initiation of depolarization and the end of repolarization of the ventricular myocardium. Excessive prolongation of this interval may drive to a potentially fatal ventricular tachyarrhythmia known as “torsades de pointes”. Agents used to manage many endocrine disorders have been linked with QTc alterations. Among them, oral antidiabetic agents, lipid lowering and anti-obesity drugs, somatostatin analogues, thyroid and anti-thyroid agents, and adrenal steroids should be considered. Nevertheless, it is very well known that some endocrine diseases are associated with constraints in the repolarization reserve, and, as a consequence, with QTc prolongation. Besides, some disturbances in the clearance of certain drugs are more frequent in patients affected by selected endocrine entities. Taking these into account, the purpose of this article is to review the behavior of the most widely used drugs in endocrinology with regards to their potential QTc prolongation effect in human beings.
Export Options
About this article
Cite this article as:
Gonzalez Daniel Claudio, de Sereday Martha, Sinay Isaac and Santoro Silvina, Endocrine Therapies and QTc Prolongation, Current Drug Safety 2010; 5 (1) . https://dx.doi.org/10.2174/157488610789869157
DOI https://dx.doi.org/10.2174/157488610789869157 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Usefulness of 5 Minutes <sup>123</sup>I-mIBG Scan in Parkinson’s Disease and Heart Failure
Current Radiopharmaceuticals Cancer Proteomics: New Horizons and Insights into Therapeutic Applications
Current Proteomics Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention
Current Drug Targets Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Contrast Echocardiography: An Update on Clinical Applications
Current Pharmaceutical Design Pregnancy Complicated by the Most Frequent Forms of Maturity Onset Diabetes of the Young: A Narrative Review on Its Pharmacological Implications
Current Reviews in Clinical and Experimental Pharmacology Selective Serotonin Reuptake Inhibitors in Pregnancy
Current Medicinal Chemistry Dopamine: The Forgotten Felon in Type 2 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Manoyl-Oxide Biotransformations with Filamentous Fungi
Current Organic Chemistry Recent Advances in the Development of MMPIs and APNIs Based on the Pyrrolidine Platforms
Mini-Reviews in Medicinal Chemistry Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Disease-Specific iPS Cell Models in Neuroscience
Current Molecular Medicine Compounds that Combine Aldose Reductase Inhibitory Activity and Ability to Prevent the Glycation (Glucation and/or Fructation) of Proteins as Putative Pharmacotherapeutic Agents
Drug Design Reviews - Online (Discontinued)